Guggenheim Reiterates Buy Rating on Illumina, Inc. with $200 Target
Guggenheim maintains its positive outlook on Illumina, Inc., setting a target price of $200, a 13.75% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Illumina, Inc. (ILMN) with a $200 price target on June 29, 2026.
- Guggenheim's $200 price target implies 13.75% upside from Illumina, Inc.'s ($ILMN) current $175.83 share price.
- Illumina shares traded at $176.55 on Monday, with a market cap of $26.7 billion and a P/E ratio of 32.04.
- BlackRock increased its holdings by 701,913 shares, while Capital World Investors reduced its position by 4,551,213 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim has reiterated its buy rating on Illumina, Inc. (NasdaqGS: ILMN), setting a price target of $200. This reaffirmation by analyst Subbu Nambi came on June 29, 2026, as the firm continues to see potential upside in the company.
Other Institutional Activity in Illumina
BlackRock, Inc. grew its holdings by 701,913 shares, ending with 19,023,590 shares worth about $2.34 billion. Meanwhile, Capital World Investors reduced its position by 4,551,213 shares, bringing its total to 15,549,960 shares valued at approximately $1.92 billion. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, with holdings of 6,823,654 and 6,594,836 shares, respectively. State Street Corp added 239,230 shares, totaling 6,429,344 shares valued at $792.5 million.
Illumina, Inc. Stock Down 18.4%
Shares of NasdaqGS:ILMN traded near $176.55 on Monday. Illumina has a market cap of $26.7 billion, a P/E ratio of 32.04, and a beta of 1.49. The stock's 52-week low is $88.00, and its high is $182.84. It has a 50-day moving average of $148.99 and a 200-day moving average of $128.54. The company's current ratio is 1.75, with a quick ratio of 1.23 and a debt-to-equity ratio of 95.07.
$ILMN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Illumina reported revenue of $4.39 billion, with a growth rate of 4.8%. The company's earnings per share (EPS) stood at $5.51, while its net margin was 19.4%. Return on equity (ROE) was 33.8%. The company is expected to announce its next earnings on July 30, 2026.
Insider Buying and Selling at Illumina, Inc.
On June 25, 2026, Chief Legal Officer Scott Davies sold 615 shares at an average price of $180 under a Rule 10b5-1 plan. Daniel Skovronsky bought 1,674 shares at $164.28 on June 16, 2026. Patricia Leckman, the SVP and Chief People Officer, sold 783 and 784 shares on June 5 and June 2, respectively, both under planned sales.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating on Illumina with a $200 price target. Bernstein reinstated coverage with a hold rating and a $185 target on June 26, 2026. Barclays maintained a sell rating with a target of $145 on June 24, 2026. The consensus among 19 analysts is a buy, with a mean price target of $151.68.
About Illumina, Inc.
Illumina, Inc. is a healthcare company specializing in genetic and genomic analysis solutions. Based in San Diego, California, the company provides sequencing instruments and consumables, targeting research centers, academic institutions, and pharmaceutical companies. Led by CEO Jacob Thaysen, Ph.D., Illumina employs about 8,600 people and collaborates with various partners to advance research in fields like oncology and rare diseases.
Bottom Line
Guggenheim's reiterated buy rating on Illumina, Inc. underscores its confidence in the company's future prospects, with a price target of $200. Investors closely watch analyst ratings for insights into potential stock performance. It's important to remember that these ratings are based on past performance and projections and may not reflect future market conditions.
Get Illumina, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ILMN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.